Personalizing prevention
How PlaqueTec’s new catheter could enable personalized CV preventive care
PlaqueTec Ltd. is working to bring personalized medicine to the cardiovascular space with a device that samples local concentrations of molecules near atherosclerotic plaques. By using these samples to identify prognostic and predictive biomarkers, the company hopes to be able to direct tailored treatments to those who will benefit most, improving both outcomes for patients and uptake of new therapies.
The cardiovascular prevention market relies on broad use of inexpensive generics such as statins, beta blockers and angiotensin-converting enzyme (ACE) inhibitors. New entrants have had to fight to make inroads even when they have data showing improvements in health and/or pharmacoeconomic outcomes...
BCIQ Company Profiles
BCIQ Target Profiles